GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » 3-Year EPS without NRI Growth Rate

China National Accord Medicines (SZSE:000028) 3-Year EPS without NRI Growth Rate : 1.10% (As of Mar. 2024)


View and export this data going back to 1993. Start your Free Trial

What is China National Accord Medicines 3-Year EPS without NRI Growth Rate?

China National Accord Medicines's EPS without NRI for the three months ended in Mar. 2024 was ¥0.77.

During the past 12 months, China National Accord Medicines's average EPS without NRI Growth Rate was -3.20% per year. During the past 3 years, the average EPS without NRI Growth Rate was 1.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 3.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of China National Accord Medicines was 94.10% per year. The lowest was -38.20% per year. And the median was 15.25% per year.


Competitive Comparison of China National Accord Medicines's 3-Year EPS without NRI Growth Rate

For the Medical Distribution subindustry, China National Accord Medicines's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China National Accord Medicines's 3-Year EPS without NRI Growth Rate Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's 3-Year EPS without NRI Growth Rate falls into.



China National Accord Medicines 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


China National Accord Medicines  (SZSE:000028) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


China National Accord Medicines 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
Executives
Su Wei Wei Independent director
Chen Chang Bing Secretary Dong
Peng Juan Director
Fu Ming Zhong Director

China National Accord Medicines (SZSE:000028) Headlines

No Headlines